Advanced diagnostics like Signatera ctDNA and therapies such as adjuvant nivolumab, while becoming standard in the US, are often unavailable in Europe and elsewhere. This creates a significant gap in care, making many cutting-edge discussions purely theoretical for a large portion of the world's oncologists and patients.
In early-stage bladder cancer, where the goal is a cure, the argument to "save a therapy for later" is flawed. The primary objective should be to use the most effective treatment upfront. Withholding it doesn't make it more effective upon relapse; it just gives the cancer an opportunity to progress.
While new systemic agents dominate MIBC discussions, chemo-radiation remains a critical treatment, especially for patients unsuitable for radical cystectomy due to age or comorbidities. For these individuals, it offers a potentially curative, bladder-preserving alternative that avoids the high risks and sequelae of major surgery.
In cisplatin-ineligible muscle-invasive bladder cancer, neoadjuvant enfortumab vedotin plus pembrolizumab demonstrated a 57% pathologic complete response rate in the KEYNOTE-905 trial. This is an unprecedented result, significantly higher than any previously studied regimen and signals a major shift in perioperative treatment.
The NIAGRA study used a creatinine clearance threshold of 40 ml/min for cisplatin, lower than the traditional 60 ml/min cutoff. This forward-looking design validates the practice of treating patients with borderline renal function with cisplatin, potentially allowing more individuals with MIBC to benefit from this chemotherapy.
As neoadjuvant enfortumab vedotin plus pembrolizumab (EVP) achieves high pathologic complete response rates in MIBC, a critical question emerges: is adjuvant EVP necessary for everyone? Continuing treatment in patients who are already cancer-free post-surgery may offer no extra benefit while increasing toxicity.
Circulating tumor DNA (ctDNA) is a powerful tool in bladder cancer. A positive result post-surgery is a strong indicator for initiating adjuvant therapy. However, a negative result does not guarantee a cure, as a notable percentage of these patients still relapse, making clinicians cautious about withholding treatment based on a single negative test.
The TAR-200 system uses a familiar drug, gemcitabine, but its novelty and efficacy stem from its delivery method. An intravesical device provides continuous, localized drug exposure to the bladder tumor, a significant departure from the short concentration peaks of standard instillation, aiming for better outcomes with fewer systemic effects.
Clinicians must weigh the immediate benefits of adding a PD-1 inhibitor for non-muscle-invasive bladder cancer against the potential loss of efficacy for crucial systemic therapies like EV-pembro if the disease later becomes metastatic. This introduces a new layer of long-term treatment strategy from the first diagnosis.
Trials like CREST and Potomac show a consistent but modest event-free survival benefit when adding a PD-1 inhibitor to BCG for high-risk non-muscle-invasive bladder cancer. However, this comes with significant toxicity and no current overall survival benefit, creating a complex risk-benefit discussion for patients.
Experts suggest urinary tumor DNA (utDNA) may better reflect local disease in the bladder, while circulating tumor DNA (ctDNA) indicates systemic disease. Using both tests in parallel could provide a more complete picture, with dual-negative results potentially becoming a key criterion for safely pursuing bladder-sparing approaches.